BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7988721)

  • 1. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin.
    Lu H; Yeh P; Guitton JD; Mabilat C; Desanlis F; Maury I; Legrand Y; Soria J; Soria C
    FEBS Lett; 1994 Dec; 356(1):56-9. PubMed ID: 7988721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
    Mirshahi SS; Lounes KC; Lu H; Pujade-Lauraine E; Mishal Z; Bénard J; Bernadou A; Soria C; Soria J
    FEBS Lett; 1997 Jul; 411(2-3):322-6. PubMed ID: 9271229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1.
    Lamfers ML; Grimbergen JM; Aalders MC; Havenga MJ; de Vries MR; Huisman LG; van Hinsbergh VW; Quax PH
    Circ Res; 2002 Nov; 91(10):945-52. PubMed ID: 12433840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells.
    Lu H; Mabilat C; Yeh P; Guitton JD; Li H; Pouchelet M; Shoevaert D; Legrand Y; Soria J; Soria C
    FEBS Lett; 1996 Feb; 380(1-2):21-4. PubMed ID: 8603739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction.
    Li C; Liu JN; Gurewich V
    J Biol Chem; 1995 Dec; 270(51):30282-5. PubMed ID: 8530448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells.
    Del Rosso M; Anichini E; Pedersen N; Blasi F; Fibbi G; Pucci M; Ruggiero M
    Biochem Biophys Res Commun; 1993 Jan; 190(2):347-52. PubMed ID: 8381273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
    Hudson MA; McReynold LM
    Adv Exp Med Biol; 1999; 462():399-412. PubMed ID: 10599442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
    Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
    Eur J Biochem; 1992 Apr; 205(2):451-8. PubMed ID: 1374026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator up-regulates its own expression by endothelial cells and monocytes via the u-PAR pathway.
    Li C; Zhang J; Jiang Y; Gurewich V; Chen Y; Liu JN
    Thromb Res; 2001 Aug; 103(3):221-32. PubMed ID: 11672584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor.
    Anichini E; Fibbi G; Pucci M; Caldini R; Chevanne M; Del Rosso M
    Exp Cell Res; 1994 Aug; 213(2):438-48. PubMed ID: 8050501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated.
    Fabbrini MS; Carpani D; Bello-Rivero I; Soria MR
    FASEB J; 1997 Nov; 11(13):1169-76. PubMed ID: 9367352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
    Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
    Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices.
    Kroon ME; Koolwijk P; van Goor H; Weidle UH; Collen A; van der Pluijm G; van Hinsbergh VW
    Am J Pathol; 1999 Jun; 154(6):1731-42. PubMed ID: 10362798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective localization of receptors for urokinase amino-terminal fragment at substratum contact sites of an in vitro-established line of human epidermal cells.
    Del Rosso M; Pedersen N; Fibbi G; Pucci M; Dini G; Anichini E; Blasi F
    Exp Cell Res; 1992 Dec; 203(2):427-34. PubMed ID: 1333982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
    Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S
    Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor.
    Masucci MT; Pedersen N; Blasi F
    J Biol Chem; 1991 May; 266(14):8655-8. PubMed ID: 1851152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.